Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9478955 | 0.87 | KMT2A (0.36) | KDM4ESMN1; SMN2CYP1A2ALDH1A1MEN1 | |
| SCHEMBL1903196 | 0.86 | KMT2A (0.34) | ALOX15TSHRCASP1KDM4ESMN1; SMN2 | |
| SCHEMBL16294271 | 0.84 | LTA4H (0.47) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8125303 | 0.83 | KMT2A (0.34) | KDM4ESMN1; SMN2CYP1A2ALDH1A1MEN1 | |
| SCHEMBL8118163 | 0.81 | ALDH1A1 (0.40) | TSHRKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL28070090 | 0.80 | EPHX2 (0.50) | LMNATDP1 | |
| SCHEMBL8131986 | 0.80 | ALDH1A1 (0.42) | TSHRKDM4ESMN1; SMN2CYP1A2MAOB | |
| SCHEMBL8119388 | 0.79 | PGR (0.40) | TSHRSMN1; SMN2CYP1A2ALDH1A1MEN1 | |
| SCHEMBL15527899 | 0.79 | HPGD (0.34) | TSHRKDM4ESMN1; SMN2CYP1A2ADORA3 | |
| SCHEMBL295086 | 0.79 | GAA (0.42) | TSHRKDM4ESMN1; SMN2ALDH1A1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1826106-A | Therapeutic agent for skin pigmentation | INST MED MOLECULAR DESIGN INC (JP) | 2006-08-30 | — | — | CN | claimed |
| CN-1265033-A | Certain diarylimidaozle derivatives, new class of NPY speific ligands | NEUROGEN CORP (US) | 2000-08-30 | — | — | CN | claimed |
| EP-0996443-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-05-03 | — | — | EP | claimed |
| WO-1999001128-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-14 | — | — | WO | claimed |
| EP-3962559-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | University of Houston System (US) | 2022-03-09 | — | — | EP | disclosed |
| US-10849886-B2 | Combination therapy using azabicyclo compound for cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| WO-2020219963-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20170216261-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-20140288127-A1 | Novel Alkene Oxindole Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-8778973-B2 | Alkene oxindole derivatives | HOFFMANN-LAROCHE INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130131114-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| CN-1104418-C | Benzoheterocyclic derivatives | OTSUKA PHARMA CO LTD (JP) | 2003-04-02 | — | — | CN | disclosed |
| US-6515133-B1 | Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-6121260-A | Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives | NEUROGEN CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |
| CN-1265033-A | Certain diarylimidaozle derivatives, new class of NPY speific ligands | NEUROGEN CORP (US) | 2000-08-30 | — | — | CN | disclosed |
| EP-0996443-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999001128-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |
| CN-1150799-A | Benzoheterocyclic derivatives | OTSUKA PHARMA CO LTD (JP) | 1997-05-28 | — | — | CN | disclosed |
| US-4202814-A | AZO DYES GIVING FAST RED COLOR | CIBA-GEIGY CORPORATION (US) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216261-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | HSP90AB1, HSP90AA1, HSP90AB2P | ALOX15 3137/4885TSHR 3916/4885CASP1 1707/4885 |
| US-10849886-B2 | Combination therapy using azabicyclo compound for cancer | HSP90AB1, HSP90AA1, HSP90AB2P | ALOX15 3137/4885TSHR 3916/4885CASP1 1707/4885 |
| US-20140288127-A1 | Novel Alkene Oxindole Derivatives | PRKAB1, PRKAR2A, PRKAB2 | ALOX15 2014/4885TSHR 1361/4885CASP1 2228/4885 |
| US-20130131114-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | PRKAB1, PRKAR2A, PRKAB2 | ALOX15 2014/4885TSHR 1361/4885CASP1 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.